Zofran: Effective Relief from Nausea and Vomiting
| Product dosage: 4mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.49 | $44.20 (0%) | 🛒 Add to cart |
| 120 | $0.44 | $58.93 $53.24 (10%) | 🛒 Add to cart |
| 180 | $0.39 | $88.40 $70.32 (20%) | 🛒 Add to cart |
| 270 | $0.35 | $132.60 $95.43 (28%) | 🛒 Add to cart |
| 360 | $0.33
Best per pill | $176.80 $120.54 (32%) | 🛒 Add to cart |
| Product dosage: 8mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.92 | $55.25 (0%) | 🛒 Add to cart |
| 90 | $0.85 | $82.87 $76.35 (8%) | 🛒 Add to cart |
| 120 | $0.80 | $110.50 $96.44 (13%) | 🛒 Add to cart |
| 180 | $0.76 | $165.75 $137.62 (17%) | 🛒 Add to cart |
| 270 | $0.74 | $248.62 $198.90 (20%) | 🛒 Add to cart |
| 360 | $0.72
Best per pill | $331.50 $259.17 (22%) | 🛒 Add to cart |
Synonyms
| |||
Zofran (ondansetron) is a prescription medication classified as a 5-HT3 receptor antagonist, specifically developed to manage and prevent nausea and vomiting. It is widely utilized in clinical settings for patients undergoing chemotherapy, radiation therapy, and postoperative recovery. By selectively blocking serotonin receptors in the brain and gastrointestinal tract, Zofran interrupts the signals that trigger emesis, offering a targeted and reliable therapeutic option. Its efficacy and favorable safety profile have made it a cornerstone in antiemetic therapy for both adult and pediatric populations.
Features
- Active ingredient: Ondansetron hydrochloride
- Available formulations: Oral tablets, orally disintegrating tablets, oral solution, and injectable solution
- Mechanism of action: Selective 5-HT3 receptor antagonist
- Onset of action: Oral forms typically within 1–2 hours; IV administration within minutes
- Duration of effect: Up to 24 hours with standard dosing
- FDA-approved for prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting
Benefits
- Provides rapid and effective control of nausea and vomiting across multiple clinical scenarios
- Reduces the risk of dehydration and electrolyte imbalances associated with persistent emesis
- Supports adherence to chemotherapy regimens by mitigating treatment-related side effects
- Available in multiple formulations to accommodate patient-specific needs and preferences
- Demonstrated safety and efficacy in pediatric patients aged 6 months and older
- Minimizes postoperative complications and facilitates smoother recovery
Common use
Zofran is primarily indicated for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin-based regimens. It is also used for moderately emetogenic chemotherapy, total body irradiation, and fractionated abdominal radiation. In surgical settings, it is administered to prevent postoperative nausea and vomiting (PONV). Off-label uses may include hyperemesis gravidarum (under careful obstetric supervision), gastroenteritis-related vomiting in certain cases, and nausea associated with opioid analgesia or vertigo.
Dosage and direction
Dosing varies based on indication, patient age, and formulation:
For chemotherapy-induced nausea and vomiting (adults):
- Oral: 24 mg taken 30 minutes before chemotherapy, or 8 mg twice daily
- IV: 0.15 mg/kg administered 30 minutes before chemotherapy, repeated 4 and 8 hours after first dose
For radiotherapy-induced nausea and vomiting:
- Oral: 8 mg taken 1–2 hours before radiotherapy, with subsequent doses every 8 hours
For postoperative nausea and vomiting:
- IV: 4 mg administered immediately before anesthesia induction or postoperatively
Pediatric dosing (chemotherapy-induced):
- Oral (aged 4–18 years): 4 mg taken 30 minutes before chemotherapy, with subsequent doses every 8 hours for 1–2 days after chemotherapy
- IV: 0.15 mg/kg before chemotherapy, repeated 4 and 8 hours after first dose
Always follow prescribing physician instructions. Tablets should be swallowed whole with water; orally disintegrating tablets are placed on the tongue and dissolve without water.
Precautions
Patients should inform their healthcare provider of any history of cardiovascular disease, as Zofran may prolong the QT interval. Electrolyte imbalances (e.g., hypokalemia, hypomagnesemia) should be corrected prior to administration. Use with caution in patients with hepatic impairment; dose adjustment may be necessary. Zofran may cause dizziness or drowsiness—caution is advised when operating machinery or driving. Serotonin syndrome is a potential risk, particularly when used concomitantly with other serotonergic drugs.
Contraindications
Zofran is contraindicated in patients with known hypersensitivity to ondansetron or any component of the formulation. Concomitant use with apomorphine is contraindicated due to risk of profound hypotension and loss of consciousness. It should not be used in patients with congenital long QT syndrome or those with a known history of torsades de pointes.
Possible side effect
Common side effects include headache (occurring in up to 25% of patients), constipation, diarrhea, fatigue, and dizziness. Less frequently, patients may experience transient asymptomatic increases in liver enzymes, flushing, or injection site reactions. Rare but serious adverse effects include QT prolongation, arrhythmias, serotonin syndrome, and severe hypersensitivity reactions (e.g., anaphylaxis, bronchospasm). Extrapyramidal symptoms have been reported, though less commonly than with older antiemetics.
Drug interaction
Zofran may interact with drugs that prolong the QT interval, such as antiarrhythmics (e.g., amiodarone, sotalol), certain antibiotics (e.g., erythromycin), and antipsychotics (e.g., haloperidol). Concomitant use with serotonergic drugs (e.g., SSRIs, SNRIs, tramadol) may increase the risk of serotonin syndrome. Phenytoin, carbamazepine, and rifampin may reduce ondansetron plasma concentrations due to CYP450 enzyme induction. Ondansetron may antagonize the effects of tramadol.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed one. For chemotherapy or postoperative prophylaxis, timing relative to the emetogenic stimulus is critical—consult a healthcare provider if a dose is missed in these contexts.
Overdose
Symptoms of overdose may include severe headache, visual disturbances, syncope, and QT prolongation. There is no specific antidote for ondansetron overdose. Management is supportive and symptomatic, including ECG monitoring for at least 24 hours. Hemodialysis is not likely to be effective due to ondansetron’s large volume of distribution.
Storage
Store at room temperature (20–25°C or 68–77°F), away from light and moisture. Keep orally disintegrating tablets in the original blister package until use. Do not store in bathrooms or damp areas. Keep all medications out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, changing, or stopping any medication. The prescribing physician should be aware of the patient’s full medical history, concurrent medications, and potential contraindications. Dosage and administration must be individualized based on clinical context and patient-specific factors.
Reviews
Clinical studies and meta-analyses consistently demonstrate Zofran’s efficacy in reducing the incidence and severity of chemotherapy-induced and postoperative nausea and vomiting. In comparative trials, it has shown superior control compared to placebo and older antiemetics like metoclopramide, with a generally favorable side effect profile. Patient satisfaction surveys often highlight its rapid action and convenience of orally disintegrating formulations. However, some critiques note the cost compared to generic alternatives and the need for caution in patients with cardiac risk factors. Overall, it remains a first-line choice in evidence-based antiemetic guidelines.